PROM1 and central nervous system cancer: In line with our data, TMZ treatment (5–25 uM) on glioma cells grown under stem cell enriched conditions reduced proliferation and survival at very low TMZ concentrations [39] and inhibited the growth of neurosphere in CD133+ sub-population and reduced tumorigenicity [35, 40].